liothyronine

Liothyronine is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine.

Liothyronine Sodium is the sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium (3,3',5-Triiodo-L-thyronine sodium) binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).

Liothyronine (Tresitope) is a synthetic and highly active thyroid hormone that acts as an effective agonist of TRα and TRβ (Ki = 2.33 nM for both hTRα and hTRβ). It activates the TRβ1 receptor, promotes the metabolism of carbohydrates, proteins, and fats, accelerates the oxidative processes in tissue cells, maintains basal metabolic rate, and supports normal growth and development. Liothyronine can be used to induce hyperthyroidism models.

T3-KLH is a hapten-carrier protein conjugate formed by coupling T3 (thyroxine) to keyhole limpet hemocyanin (KLH). As a hapten, T3 alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity. T3-KLH may be supplied as a lyophilized powder or as a solution. The solution is prepared in 0.01 M PBS (pH 7.4) buffer at a typical concentration of 1 mg/mL.

T3-OVA is a hapten-carrier protein conjugate formed by coupling T3 (thyroxine) to chicken ovalbumin (OVA). As a hapten, T3 alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity.

T3-BSA is a hapten-carrier protein conjugate formed by coupling T3 (thyroxine) to bovine serum albumin (BSA). As a hapten, T3 alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity.

Liothyronine sodium hydrate (Triiodothyronine sodium hydrate) is a TRα and TRβ agonist and a thyroxine analog with anticancer and antitumor activities. It can be used to study hypothyroidism, stroke and cognitive dysfunction.

Liothyronine I 125 is a radioactive.

Liothyronine-13C9,15N is a Liothyronine compound labeled with isotopes 13C and 15N. It is an active thyroid hormone and an effective agonist for TRα and TRβ, exhibiting a Ki value of 2.33 nM for both hTRα and hTRβ.

Liothyronine (Standard) is a reference standard for research and analysis in studies involving Liothyronine. Liothyronine (Tresitope) is a synthetic and highly active thyroid hormone that acts as an effective agonist of TRα and TRβ (Ki = 2.33 nM for both hTRα and hTRβ). It activates the TRβ1 receptor, promotes the metabolism of carbohydrates, proteins, and fats, accelerates the oxidative processes in tissue cells, maintains basal metabolic rate, and supports normal growth and development. Liothyronine can be used to induce hyperthyroidism models.

ZTA-261 is a highly selective and low-toxicity agonist for the thyroid hormone receptor subtype β (THR-β), with an IC50 of 6.3 nM. It operates through the Liothyronine-mediated pathway to reduce body weight and visceral fat. This compound has applications in the study of lipid metabolism and obesity.